Kennedy Capital Management LLC Has $1.39 Million Stake in The Shyft Group, Inc. (NASDAQ:SHYF)
Kennedy Capital Management LLC lifted its position in shares of The Shyft Group, Inc. (NASDAQ:SHYF – Free Report) by 516.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 92,571 shares of the company’s stock after buying an additional 77,559 […]
More Stories
Eureka Resources Inc., Prior to Reverse Merger with Kore Mining (CVE:EUK) Stock Crosses Above Fifty Day Moving Average – Here’s What Happened
Eureka Resources Inc., Prior to Reverse Merger with Kore Mining Ltd. (CVE:EUK – Get Free Report)’s share price passed above...
Metals Acquisition Limited (ASX:MAC) Insider Michael (Mick) McMullen Buys 16,957 Shares of Stock
Metals Acquisition Limited (ASX:MAC – Get Free Report) insider Michael (Mick) McMullen bought 16,957 shares of Metals Acquisition stock in...
NanoVibronix (NASDAQ:NAOV) Enters into Securities Exchange AgreementOn January 7, 2025, NanoVibronix, Inc. filed an 8-K form with the Securities and Exchange Commission, disclosing its recent agreement with an institutional investor. The company ente
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
**Freddie Mac Appoints James Whitlinger as EVP & CFO**McLean, Va. – Freddie Mac (OTCQB: FMCC) has recently revealed the appointment of James Whitlinger as Executive Vice President and Chief Financial Officer (CFO), effective January 1, 2025. Whitling
* This article was generated by an automated content engine and was reviewed by a human editor prior to publication....
Oxbridge Re Holdings Reports Potential Underwriting Losses in Connection with Hurricanes Helene and Milton
Oxbridge Re Holdings Limited (NASDAQ: OXBR) recently disclosed potential underwriting losses in a Current Report on Form 8-K. The losses...
Stoke Therapeutics Prepares for Phase 3 Study of Zorevunersen for Dravet Syndrome
Stoke Therapeutics, Inc. (NASDAQ: STOK) recently announced plans to launch a Phase 3 study of zorevunersen, aiming to develop the...